Pimecrolimus 1% cream for the treatment of rosacea

Rosacea is a common inflammatory skin disorder; the pathogenesis is unclear. Various treatment options for rosacea are available, but most have limited effectiveness. The aim of this study was to investigate the efficacy and safety of 1% pimecrolimus cream for the treatment of rosacea. Thirty patien...

Full description

Saved in:
Bibliographic Details
Published in:Journal of dermatology 2011-12, Vol.38 (12), p.1135-1139
Main Authors: KIM, Moon-Bum, KIM, Gun-Wook, PARK, Hyun-Je, KIM, Hoon-Soo, CHIN, Hyun-Woo, KIM, Su-Han, KIM, Byung-Soo, KO, Hyun-Chang
Format: Article
Language:English
Subjects:
Administration, Topical
calcineurin inhibitor
Calcineurin Inhibitors
Dermatologic Agents - administration & dosage
Female
Humans
Male
Middle Aged
pimecrolimus
rosacea
Rosacea - drug therapy
Rosacea - pathology
Tacrolimus - administration & dosage
Tacrolimus - analogs & derivatives
Treatment Outcome
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Rosacea is a common inflammatory skin disorder; the pathogenesis is unclear. Various treatment options for rosacea are available, but most have limited effectiveness. The aim of this study was to investigate the efficacy and safety of 1% pimecrolimus cream for the treatment of rosacea. Thirty patients with rosacea were enrolled in this 4‐week, single‐center, open‐label study of 1% pimecrolimus cream. Patients were instructed to apply the cream to their faces twice daily and were not permitted to use any other agents. Clinical efficacy was evaluated by a rosacea grading system using photographic documentation and a mexameter. The 26 patients who completed the study experienced significantly reduced rosacea clinical scores from 9.65 ± 1.79 at baseline to 7.27 ± 2.11 at the end of treatment (P 
ISSN:0385-2407
1346-8138
DOI:10.1111/j.1346-8138.2011.01223.x